On June 1, 2022 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York (Press release, Aclaris Therapeutics, JUN 1, 2022, View Source [SID1234615334]). Management will be available June 8th for 1×1 meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

On June 1, 2022 Alkermes plc (Nasdaq: ALKS) reported that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m. BST) (Press release, Alkermes, JUN 1, 2022, View Source [SID1234615333]). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 1, 2022 The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all types of cancer, reported the publication of its newest analysis of the global landscape of cellular immunotherapies, including R&D trends and real-world usage data (Press release, Cancer Research Institute, JUN 1, 2022, View Source [SID1234615332]). The report, published today in Nature Reviews Drug Discovery, highlights trends in cellular immunotherapy for cancer including top modalities, targets, clinical development, and data from patients receiving CAR-T therapies in clinical practice. This report is an update to CRI’s prior cellular immunotherapy landscape analysis published in July 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this analysis, author Samik Upadhaya, Ph.D., assistant director of scientific affairs and member of the Anna-Maria Kellen Clinical Accelerator team at CRI, and colleagues provide an update on the overall status of the cellular cancer immunotherapy landscape as well as observations on key changes within the field including clinical practice. Findings include:

As of April 15, 2022, there were 2,756 active cell therapy agents in the global immuno-oncology pipeline, an increase of 36% over the 2021 landscape analysis that identified 2,031 such agents, but also a modest deceleration compared to 43% growth in the prior year
CAR-T therapeutics continue to dominate the cell therapy pipeline with growth of 24% since 2021
Development continues for non-T cell therapies including NK cell, dendritic cell, stem cell, and other myeloid-derived cell therapies, with the greatest growth in NK cell therapy, up 55% over the prior year
Clinical usage of cell therapy for cancer treatment is not keeping pace with regulatory approvals, with clinicians citing cost, travel, and supply limitations as key barriers to patient access
This latest report from the Cancer Research Institute, titled, "Landscape of cancer cell therapies: trends and real-world data," was generated in collaboration with IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, which provided the authors with access to IQVIA’s proprietary clinical trials database. The report is part of a suite of CRI-owned immuno-oncology landscape analyses that includes reports on cell therapy drug development and the broader IO landscape including clinical development of checkpoint inhibitors, cancer vaccines, and oncolytic viruses in addition to bispecific antibodies and other immunomodulators.

To access an interactive dashboard of the Cancer Research Institute’s cancer cell immunotherapy report, visit the CRI website at cancerresearch.org/cell-therapy.

On June 1, 2022 Herantis Pharma Plc ("Herantis" or the "Company"), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, reported on 3 May 2022 that the Board of Directors of Herantis had decided to offer Herantis’ shareholders up to 4,831,426 new shares (the "Offer Shares") in a rights issue on the basis of shareholders’ pre-emptive subscription rights in the same proportion as they already hold shares in the Company and secondarily by other shareholders or by other persons (the "Offering") (Press release, Herantis Pharma, JUN 1, 2022, View Source,c3578594 [SID1234615331]). According to the final results of the Offering, Herantis received gross proceeds of approximately EUR 7.25 million from the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The final results of the Offering show that the Offering was subscribed in full. Approximately 81.1 per cent of the 4,831,426 Offer Shares were subscribed for with subscription rights. The remaining approximately 18.9 per cent of the Offer Shares were allocated in accordance with the terms and conditions of the Offering in the secondary subscription to subscribers who subscribed for Offer Shares also with subscription rights. No Offer Shares were allocated to subscribers who subscribed for Offer Shares only without subscription rights in the secondary subscription in accordance with the terms and conditions of the Offering. The subscription price in the Offering was EUR 1.50 per Offer Share in Finland and SEK 15.60 per Offer Share in Sweden.

Herantis’ Board of Directors has today approved the subscriptions made in the Offering, and allocated the Offer Shares to be issued, in accordance with the terms and conditions of the Offering. As a result of the Offering, the total number of shares in Herantis will increase by 4,831,426 from 12,078,568 to 16,909,994. The Offer Shares issued in the Offering amount to approximately 28.6 per cent of the outstanding shares in Herantis following the Offering.

The last day of trading in the interim shares on Nasdaq First North Growth Market Finland ("First North Finland") will be on or about 2 June 2022 and on Nasdaq First North Growth Market Sweden ("First North Sweden") on or about 9 June 2022. The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 2 June 2022. The interim shares will be combined with the Company’s existing shares once the Offer Shares have been registered with the Finnish Trade Register. The combination will take place on or about 3 June 2022 in Finland and on or about 10 June 2022 in Sweden. The trading in the Offer Shares on First North Finland will commence on or about 3 June 2022 and on First North Sweden on or about 10 June 2022. The Offer Shares confer the same rights as Herantis’ other shares, after being registered with the Finnish Trade Register and delivered on the investor’s book-entry account, on or about 3 June 2022 in Finland and on or about 10 June 2022 in Sweden.

UB Securities Ltd is acting as the lead manager of the Offering. Krogerus Attorneys Ltd is acting as the legal counsel to the Company as to Finnish law and Advokatfirman Cederquist KB as to Swedish law.

On June 1, 2022 OncoNano Medicine, Inc. reported the appointment of Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer (Press release, OncoNano Medicine, JUN 1, 2022, View Source [SID1234615330]). Dr. Krishnan will be responsible for formulating and leading all clinical development efforts and operations at OncoNano. Additionally, Dr. Krishnan will develop and implement the strategic clinical plans for OncoNano, including the creation of a medical affairs team, as the company further advances its clinical oncology development programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled that OncoNano has been successful in attracting such a noted and impressive scientist as Dr. Krishnan. Kartik is a proven and respected oncology drug developer, with extensive experience in leading the development of novel oncology therapeutic programs," said Martin Driscoll, CEO of OncoNano. "His breadth of experience and history of drug development success will be instrumental to our company as we progress our differentiated portfolio of oncology development candidates into multiple clinical trials."

Dr. Krishnan previously served as Chief Medical Officer at Arcus Biosciences, where he led the expansion of the company’s portfolio into novel indications and combinations, as well as the initiation of a number of pivotal Phase 3 trials. Prior to joining Arcus, he served as Executive Medical Director at Astex Pharmaceuticals, providing strategic direction and tactical support across multiple programs in all phases of development. Dr. Krishnan has also held positions in clinical drug development at Genentech, FivePrime Therapeutics, BioMarin and Amgen. Dr. Krishnan earned both his M.D. and Ph.D. in Cellular, Molecular, and Biophysical Studies from Columbia University.

"My passion is working with novel technologies that have the potential to benefit the treatment of patients with cancer. I am excited about the potential for the core platform technology at OncoNano that can deliver oncology payloads in a targeted and efficient manner to the tumor microenvironment," said Dr. Krishnan. "I believe I am joining OncoNano at an ideal time because I can immediately impact the strategic development plans for the OncoNano therapeutics programs and lead the execution of the clinical programs at the company. I am impressed with the OncoNano organization and look forward to working with Marty and the OncoNano team to successfully advance our pipeline and achieve the company’s mission to benefit cancer patients."